The Value of Support Groups

Dorothy Leone-Glasser, RN, HHC, CEO Advocates for Responsible Care,

Chair Georgia Bio Patient Advocacy Alliance

When I was diagnosed with systemic lupus erythematosus at 19 years, I discovered a major void in the treatment of chronic illness –support counseling to help patients understand and cope with the challenges of their disease. To bridge this gap in my own practice as a Nurse Specialist, I took a 3-year internship in Chronic Illness Counseling at Columbia University, NYC.  I was determined to fill that void so I created, a national award winning, Coping with Chronic Illness Project. The major component was providing support groups for those with chronic and terminal illness and their caregivers. The groups offered information and practical life-style engineering methods to address the physical and psychological aspects of illness, coping methods, pain and stress management strategies and communication and relationship skills with navigation approaches to our complex healthcare system.

Today we are partnering with GA Bio-Center for Global Health Innovation (CGHI) to focus on the science of patient input for medical research and development with consideration of downstream regulatory and legislative policy decision making.  In doing so, we can explore gaps in knowledge and other barriers that impede progress, and discuss the value of patient input for research that addresses gaps and barriers that could help move the patient and Bio community forward.

To understand the value of support groups on our patient community, Rx in Reach and CGHI launched a digital campaign to collect survey responses from Georgians about chronic illness support groups through Facebook Ads.

The survey generated 157 responses with 49% of all responders saying they belonged to a chronic illness support group. Although, 45% of all responders said they don’t belong to a support group for chronic illness; 63% of all responders said they would like to join a support group.

Other interesting findings from our survey were:

  • 60% believe support groups are misunderstood 
  • 46% said there a stigma associated with support groups that could lead to members feeling embarrassed
  • Responders stated they joined a support group because of
    • feeling isolated
    • needing help managing illness
    • needing someone to listen
    • their physician suggested it

Our findings show there is a strong stigma associated with seeking help from a support group. Support group members believe the public does not understand the need to connect with others who understand their daily challenges of living with chronic illness. Professional facilitated support groups offer a safe, non-judging environment for people to gain valuable information about disease processes, managing illness symptoms and healthcare system barriers while providing worthwhile life-style engineering to better cope with the rollercoaster of emotions and daily living complications. Survey responders, 20%, stated, their support group experience helped them, especially to feel less isolated and 15% of responders stated their group offered them the opportunity to gain new friends who understand their illness journey.

Summary

We know there are many with chronic illness, their caregivers, family members and friends who would want the chance to join a support group. This presents an opportunity for us to extend our outreach to those who are facing illness feeling alone and misunderstood so we can ensure their voices are heard with aid and encouragement offered to help them live their best life despite being ill. The work of this Patient Advocacy Alliance will continue to bring together our Bio community, patient support group members, advocate and medical organizations to improve health equity throughout our healthcare delivery system and clinical trials, while sharing strategy and actions that address important health policy issues.

Panelists

Kelly Barta headshot

Kelly Barta

Coalition of Skin Diseases, President

After experiencing a prolonged and severe health crisis due to long-term use of topical steroids for eczema, Kelly became a passionate voice for those who were suffering. She was determined to bring change to the way eczema was understood and treated. Her advocacy efforts have led her to serve on several national dermatology nonprofits, bringing awareness to the great needs of this community and supporting those living with eczema and going through topical steroid withdrawal syndrome.

Kelly currently serves as President and CEO of the Coalition of Skin Diseases, an umbrella organization of more than 25 national skin-related patient groups, which exists to raise awareness of skin diseases and advocate for the 84+ million Americans living with skin conditions.

She has served as past president of the International Topical Steroid Awareness Network (ITSAN), and continues to support their mission as member of the Board of Directors. Additionally, Kelly sits on the Patient Advocacy Task Force of the American Academy of Dermatology and the Atopic Dermatitis Advisory Panel for Globalskin. She has presented on eczema and TSW to the FDA as well as before patient, academic and political audiences. Kelly is the recent author of her story, To Eczema With Love, https://toeczemawithlove.com/.

Kelly resides in Atlanta, Georgia with her two sons and enjoys taking in the great outdoors, whether it be the mountains, oceans, a walk in the woods or digging in her own garden.

Barbara Fleeman headshot

Barbara Fleeman

WomenHeart Champion; Support Group Facilitator

Barbara grew up in Atlanta and moved back 6 years ago after spending 40 years building a successful career in entertainment consumer marketing/promotion.  She was always very active in her personal and professional life.  In 2013 she was diagnosed with severe pericarditis.  Over the following 18 months. She continued to experience increasingly difficult episodes of shortness of breath, chest pain, fatigue, nausea, dizziness, and chest pressure.  She went to see several doctors and was told that there was nothing wrong with her heart, even though she told them “My heart hurts”.  She continued to become sicker.  After a long course of indecision by medical professionals, she found help and a correct diagnosis of INOCA and Coronary Microvascular Dysfunction at the Barbra Streisand Women’s Heart Center at Cedars Sinai Medical Center in Los Angeles.

In 2015 she was invited to attend the WomenHeart Science and Leadership Symposium at the Mayo Clinic in Rochester, MN.  After an intensive five-day event, she was trained to become a WomenHeart Champion.  Barbara continues to share her experience with women to help educate them to the unique signs & symptoms of women’s heart disease, as well as, provide patient advocate support to women who are living with or at risk of heart disease.

Christopher Reed headshot

J. Christopher Reed

Lupus Foundation of America-Georgia

Support Group Facilitator, Advocacy Chair

Christopher was diagnosed with lupus in 1990 at the age of 16. Lupus attacked his heart, lungs, kidneys, digestive system, veins, and nervous system. Christopher’s lupus journey began with chronic headaches and frequent muscle spasms then progressed to frequent fevers, arthritis, and tremendous weight loss. He was barely able wrap his hands around the steering wheels during driver’s ed class and walking up the stairwell to his bedroom felt like he was having a heart attack. In 2004, he developed stage 3 kidney disease.  With his first job out of law school, Christopher was juggling kidney disease and horrible chemotherapy treatments. In 2018, he almost lost his life due to septic shock.

Overtime, Christopher continued to suffer from severe organ involvement. He was constantly worried about a lack of insurance and the cost of his life-saving medication.

Despite these serious lupus attacks, and moving back to his parent’s home, Christopher earned a bachelor’s degree with honors from the Georgia State University and a law degree from Tulane University. He attributes his success to God, the support of family and the support received at an early age from the Lupus Foundation of America, Georgia Chapter (LFAGA).

In speaking with Christopher, one can tell he is an avid advocate passionate about tackling healthcare policy and increasing lupus research. He previously chaired the Georgia Council on Lupus Education and Awareness (Council), a sponsored entity created by the state legislature to improve the lives of Georgians living with lupus.  He has worked to establish the Georgia Lupus Collaborative, an advisory group and think tank charged with improving the lives of people with lupus in Georgia.

Christopher currently serves as a Support Group Facilitator, Advocacy Chair, and Project Manager for the Lupus Foundation of America-Georgia Chapter. His support group is specifically designed for men. As Advocacy Chair, he gives presentations on patient advocacy and public health policy as well as being a writer on Lupus. Each year, over a one hundred lupus advocates engage in Lupus Day at the Georgia State Capitol. He remains involved in Health Research and serves to increase African American participation in clinical trials through a series of education sessions, open discussion, and dialogues with African American physicians and African American researchers.

Christopher has been honored to be a recipient of several awards including the Mary Cann Achievement Award from the Lupus Foundation of America, Georgia Chapter.

The post The Value of Support Groups appeared first on Georgia Bio.

By Maria Thacker Goethe July 28, 2025
By: Clary Estes “Small companies are the lifeblood of the industry and a lot of what they do, and what they’re experiencing, greatly affects the industry as a whole,” said Chad Wessel, Director of Industry Analysis at the Biotechnology Innovation Organization (BIO). He spoke with Bio.News in an interview about BIO’s 2025 report, “ The State of Emerging Biotech Companies: Investment, Deal, and Pipeline Trends ,” focused on the biotech industry from the early-stage perspective. As researchers found, the current landscape is challenging, but there are still opportunities. “In the last couple years, we’ve had a little bit of a contraction of the industry. During COVID, we kind of had this sugar rush for the industry,” said Wessel. “A lot of companies were being created. A lot of money was being thrown out there. A lot more companies were being funded. And in the last couple of years, there has been a little bit more of a correction, and we’re seeing funding levels going down to what we’ve seen prior to COVID.” “But when you add on other challenges, like the political landscape and everything, it is leaning towards a very challenging environment for a lot of companies,” he continued. Bearish venture capital “In venture capital, yes, you have a lot of money, but it’s going to fewer companies at higher average amounts,” explained Wessel. “It’s creating this competitive haves and have-nots type marketplace or environment. So it just makes it a lot more competitive and more challenging to raise funds.” Instead of finding new opportunities, venture capitalists are investing more in companies they are already working with. As the BIO report found, the amount of new series A-1 investment rounds into biopharma remained flat between 2023 and 2024, while the number of U.S. companies receiving their first series A-1 tranche went from 102 to 100. This is in comparison to 181 in 2021, reflecting the COVID influx to emerging biotechs. Comparatively, as the BIO report found, the average amount for A-1 transactions in the U.S. saw a remarkable increase of 700% in the last 15 years, with the average amount raised sitting at $60 million in 2024. The rest of the world stayed relatively steady in comparison to the U.S.’s persistent growth. And with the more bearish tendencies of investors, Wessel and team observed an interesting trend. “2024 was the first year that clinical programs actually raised more venture dollars than pre-clinical, which hasn’t happened in a while,” said Wessel. “I think the last time that happened was in 2018. This ties into some of the information that we’ve heard anecdotally, which is that a lot of VC firms are focusing on the companies that they currently have in their portfolio, rather than adding new companies.” Licensing and deals dip It is not too surprising, then, that as investors shore up what they already have in the pipelines, the R&D pipeline and licensing have slowed somewhat. As the BIO report observed, long-term growth in the R&D pipeline continues with an overall growth of 145% since 2010. Yet, the 2024 expansion rate (4.6%) subsided slightly, trailing the 5-year average of 6.7%. “The growth has slowed on new programs, and more of those programs are being licensed with larger companies,” explained Wessel. “There are fewer options for big companies to backfill their pipeline with products because a lot of them are already out.” The data also shows a notable slowing of the R&D typically done by large biopharma companies. “The areas that are not licensed out as much are the ones with some of the higher patient populations and subsequently the ones that are not being run by small companies,” said Wessel. “These are areas like endocrine and cardiovascular diseases, which are areas where there are a lot of things like type 2 diabetes, psoriasis , high blood pressure, etc. Those all have a lot of burden on the healthcare sector or the patient population, and those aren’t really being worked on that much by smaller companies.” Comparatively – and also not surprisingly – oncology has stayed at the top of the clinical pipeline, along with neurology and infectious disease. “Same thing with licensing,” said Wessel. “While there are deals that are still happening, the upfront amount is lower currently than it has been in years past, and most of the value is tied up into milestone payments, which may or may not happen.” This is also being felt when it comes to new companies going public, which has been an oft-discussed challenge in the biotech industry for the last few years. “The IPO market has still been challenging,” Wessel says. “We went from having 40 companies a year going public, down to 15 in 2023, and now we’re back up in 2025, but it’s still down from the pre-COVID era timeframe.” Biopharma layoffs Another notable characteristic of this year’s biopharma landscape has been uptick in layoffs. “Sometimes it’s just the nature of the economy. But the amount that we’ve seen in the last few years is quite a bit higher,” said Wessel. “To counter that, we don’t really have a way of measuring job creation, but we do know it’s happening. We just are unable to put a value on that.” The BIO report found that layoff announcements ticked up to 65 during Q1 of 2025. While two points lower than Q1 of the previous year, this still marks a jump from 2024’s Q2, Q3, and Q4, which saw the number of layoff announcements at 41, 54, and 46, respectively. All in all, Wessel noted, the biotech industry is still in a bit of a holding period when it comes to trying to navigate the coming months. “It’s too early to be able to say much about the coming years for the industry based on these numbers,” he said. “It takes a little time for reality to kind of catch up for multiple reasons. But what I can say is that we do know that companies are reducing their pipelines. We do know that companies are laying off individuals. We do know that companies are having a challenge of raising funds and continue doing their best to try to maintain operations as long as they can until they can get funds.” “We know the challenge is out there, but we’re going to have to kind of wait and see a little bit on the data side of things to understand how everything is going to catch up going forward.” Source: https://bio.news/bioeconomy/bio-2025-state-of-emerging-biotechs-report-market-trends/?mkt_tok=NDkwLUVIWi05OTkAAAGb7m5php-rTOf0a_GTaj5pj7Zl-HlpVM25WtyVvCYudM82a9GKjoazUg9sqU66hlAbhqbEuYvcX3C4EqfBG7Q
By Maria Thacker Goethe July 26, 2025
Pioneer Institute has released updated #340B state fact sheets for 2025
By Georgia Bio Admin July 24, 2025
GLS is proud to announce a new partnership with Apprenti This is a key step toward expanding Registered Apprenticeship programs across Georgia’s thriving life sciences sector. July 24, 2025
MORE POSTS